Investment Rating - The report maintains a "Buy" rating for the company [4][6]. Core Views - The chemical and traditional Chinese medicine segments are under short-term pressure, but several innovative products are expected to offset the impact of centralized procurement, maintaining double-digit profit growth for the year [3]. - The company achieved revenue of 6.282 billion yuan (down 6.1%) and a net profit attributable to shareholders of 1.171 billion yuan (up 3.2%) in H1 2024, with performance in line with expectations [4]. - The company continues to repurchase shares, reflecting confidence in future development [4]. Financial Summary - For H1 2024, the company reported revenue of 6.282 billion yuan, a decrease of 6.1%, and a net profit of 1.171 billion yuan, an increase of 3.2% [4]. - The second quarter of 2024 saw revenue of 3.040 billion yuan (down 7.2%) and a net profit of 563 million yuan (up 1.9%) [4]. - The company forecasts EPS for 2024-2026 to be 2.40, 2.70, and 3.09 yuan, respectively, with a target price of 43.96 yuan, corresponding to a PE of 18X for 2024 [4][6]. Business Segment Performance - The chemical preparation segment generated revenue of 3.224 billion yuan (down 7.4%), with a gross margin increase to 81.2% [4]. - The traditional Chinese medicine segment reported revenue of 745 million yuan (down 21.9%), affected by fluctuations in virus infection rates [4]. - The diagnostic reagents and equipment segment achieved revenue of 394 million yuan (up 32.3%), with rapid expansion in sales channels for infectious diseases [4]. Innovation and Development - The company is actively advancing innovative drugs and high-end formulations, with significant market potential for products like Triptorelin microspheres [4]. - The company has submitted an NDA for Semaglutide for type 2 diabetes and is preparing for phase III trials for weight loss indications [4].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price raised to 9.83 yuan from the previous 8.75 yuan [2][3]. Core Insights - The company's performance in the first half of 2024 was temporarily under pressure due to low-margin settlement projects and settlement rhythm, but an improvement is expected in the second half of the year [3]. - The company reported a revenue of 24.2 billion yuan in the first half of 2024, a year-on-year decline of 10.5%, and a net profit attributable to shareholders of 1.17 billion yuan, down 28.7% year-on-year [3]. - The company plans to deliver 22 projects in the second half of the year, primarily in the fourth quarter, with a total planned deliverable area of 4.425 million square meters, an increase of 6.8% year-on-year [3]. - The gross profit margin decreased significantly in the first half of 2024, down 8.7 percentage points to 9.6%, but is expected to improve as low-margin projects are settled and housing prices stabilize [3]. - The company has a substantial amount of unrecognized pre-sale funds amounting to 139.44 billion yuan, providing support for future performance [3]. - The company has been actively acquiring land, with a land acquisition-to-sales ratio of 0.38, ranking second among the top 10 real estate companies in terms of equity sales [3]. - The company aims to maintain financial stability and has reduced its average financing cost to a historical low of 3.7% [3]. Financial Summary - For the first half of 2024, the company reported a revenue of 24.2 billion yuan and a net profit of 1.17 billion yuan [3]. - The projected earnings per share (EPS) for 2024, 2025, and 2026 are 0.98 yuan, 1.10 yuan, and 1.22 yuan, respectively [3]. - The company’s total assets are projected to reach 343.85 billion yuan by 2024, with total liabilities of 282.57 billion yuan [11]. - The net asset value per share is 8.47 yuan, with a price-to-book ratio of 1.0 [5]. Market Data - The company's stock price has ranged from 5.78 to 11.00 yuan over the past 52 weeks, with a total market capitalization of 26.198 billion yuan [4]. - The company has a total share capital of 3.111 billion shares, with 2.682 billion shares in circulation [4]. Comparative Analysis - The company’s P/E ratio is projected to be 8.57 for 2024, compared to an industry average of 9.3 [12]. - The company ranks favorably in terms of land acquisition among its peers, indicating a strong competitive position in the market [3].

Investment Rating - The report maintains a "Buy" rating for Hisense Home Appliances [5][23] - The target price is set at 42.00 CNY [5][23] Core Views - The company's performance in H1 2024 met expectations, with significant growth in overseas revenue despite pressure in domestic HVAC sales [3][4] - The company is expected to maintain rapid growth overseas in H2 2024, with domestic sales stabilizing [3][4] Summary by Sections Performance Overview - In H1 2024, Hisense achieved revenue of 48.642 billion CNY, a year-on-year increase of 13.27%, and a net profit of 2.016 billion CNY, up 34.61% [16][18] - Q2 2024 revenue was 25.156 billion CNY, reflecting a 6.98% year-on-year growth, with net profit increasing by 17.26% to 1.035 billion CNY [16][18] Revenue Growth - Domestic revenue grew by 4% while overseas revenue surged by 28% in H1 2024, with overseas white goods business increasing by 37% [17][18] - The overall share of overseas revenue reached 37.43%, up 4.28 percentage points year-on-year [17][18] - Revenue growth by region includes Europe (+14%), Americas (+40%), Asia-Pacific (+19%), Middle East and Africa (+27%), and ASEAN (+39%), with ASEAN showing a remarkable 64% growth in proprietary brand revenue [17][18] Cost and Profitability - The company's gross margin for H1 2024 was 21.28%, a decrease of 0.25 percentage points year-on-year, while the net margin improved by 0.44 percentage points to 6.23% [20][21] - The decline in gross margin was primarily due to lower export prices in the washing and refrigeration segment and increased shipping costs [20][21] - The recovery of minority interests contributed positively to net profit, with the proportion of minority interests in net profit decreasing from 38.9% to 30.7% [20][21] Cash Flow and Financial Position - The company reported cash and cash equivalents totaling 19.153 billion CNY, with net cash improving [22] - Operating cash flow for H1 2024 was 2.1 billion CNY, down 44.91% year-on-year, primarily due to rising copper prices and increased overseas shipping costs [22] Investment Recommendations - The report maintains profit forecasts for 2024-2026, projecting net profits of 3.567 billion CNY, 4.176 billion CNY, and 4.819 billion CNY, respectively, with corresponding EPS of 2.57 CNY, 3.01 CNY, and 3.48 CNY [23]

股 票 研 究 建筑上半年业绩整体承压，中国能建/中国建筑正增长 [Table_Industry] 建筑工程业 [Table_Invest] 评级： 增持 上次评级: 增持 ——建筑行业第 363 期周报 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------|-------------------------------------|---------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | [table_Authors] 韩其成 ( 分析师 ) | 郭浩然 ( 分析师 ) | | | | | | | | | 021-38676162 | 010-83939793 | | | | | | | | | hanqicheng8@gtjas.com | guohaoran025968@gtjas.com | | | | | | | | 登记编号 | S0880516030004 | S08805 ...

Investment Rating - The report maintains an "Overweight" rating for the environmental sector, consistent with the previous rating [4]. Core Insights - The report highlights significant pressure on the power grid due to extreme weather conditions, particularly in the Sichuan and Chongqing regions, where maximum electricity loads have reached historical highs [7][8]. - The report emphasizes the acceleration of the new power system construction in response to the increasing demand for electricity and the integration of renewable energy sources [8]. - Investment recommendations include companies that specialize in low-temperature flue gas denitrification technology, smoke monitoring equipment, and flexible transformation equipment [8]. Summary by Sections Weekly Investment Perspective - The report notes that the Sichuan power grid's maximum load reached 67.97 million kilowatts, a 13% increase compared to the previous year, while Chongqing's maximum load hit a record 28.16 million kilowatts [7]. - It predicts that the total installed capacity of wind and solar power will exceed that of coal power for the first time in 2024, leading to challenges in renewable energy consumption and grid stability [8]. Environmental Sector Weekly Performance - The environmental sector index experienced a slight increase of 0.02%, while other sectors like gas and water utilities saw declines of 0.73% and 3.74%, respectively [10]. - The top five gainers in the environmental sector included Baoxin Technology (+33.24%) and Ning Shui Group (+20.71%), while the biggest losers were Guozhong Water (-31.99%) and Xingrong Environment (-13.66%) [10]. Carbon Neutrality Tracking - The national carbon market saw a transaction volume of 1.48 million tons, a 33% decrease from the previous week, with an average transaction price of 83.31 yuan/ton [12]. - Local carbon quotas traded 992,400 tons, marking a 66% increase, with an average price of 70.48 yuan/ton, up 23% from the previous week [12]. Important Events in the Environmental Sector - The report discusses the issuance of guidelines by the National Development and Reform Commission and the National Energy Administration to promote green electricity trading and enhance regulatory oversight [14]. - It also highlights the financial support for various environmental projects along the Yangtze River, aiming to improve the quality of life and ecological restoration [15]. Major Announcements from Environmental Companies - Qingda Environmental reported a 45.81% increase in revenue for the first half of 2024, with net profit rising by 85.99% [16]. - Yuhua Tian plans to raise up to 1.5 billion yuan through convertible bonds to invest in sanitation equipment and working capital [17].

Investment Rating - The report assigns a "Buy" rating to Haidilao (6862) [2] Core Views - Despite weak demand and consumption downgrade trends, Haidilao's stable operations and superior dividend payout ratio justify a higher valuation multiple of 18x PE compared to the industry average of 13x PE [4] - The target price is revised downward to RMB 14.53 (-22%), equivalent to HKD 15.89, while maintaining the "Buy" rating [4] - Haidilao's H1 2024 revenue reached RMB 21.491 billion, a 14% YoY increase, with net profit attributable to shareholders declining by 9.7% to RMB 2.038 billion [4] - Excluding tax credits and exchange gains/losses (approximately RMB 400 million), core business profit is estimated to have grown 13% YoY, aligning with the company's disclosed Non-GAAP core operating profit growth [4] Operational Performance - Turnover rates continue to recover across all store tiers: Tier 1/Tier 2/Tier 3 & below/overseas/overall at 4/4.3/4.1/4.2/4.2, showing YoY increases of 18%/23%/28%/2%/24% respectively [4] - Same-store sales growth varies significantly by region: +11%/-48%/+20%/+2%/+15% for Tier 1/Tier 2/Tier 3 & below/overseas/overall respectively [4] - Average customer spending shows a downward trend across all regions, with overall spending down 5.3% YoY [4] - Store network strategy shifts towards Tier 2 and 3 cities, with net store openings of -12/+9/+13/+10/+1/+11 in Tier 1/Tier 2/Tier 3 & below/overseas/overall respectively [4] Financial Performance - Revenue breakdown: Restaurant operations (+13.8%), other restaurants (+74.3%), delivery (+23.3%), and condiment/ingredient sales (-19.2%) [4] - Cost structure: Raw materials (39%), staff costs (33.3%), property rental (1%), depreciation (6.2%), and utilities (3.4%) [4] - Staff costs increased due to higher headcount per store (from 99 to 106 employees) and increased promotional activities [4] Financial Projections - 2024-2026 net profit forecasts revised to RMB 4.5/5.0/5.4 billion, with EPS of RMB 0.81/0.90/0.98 [4] - Revenue projections: 2024E RMB 44.960 billion (+8.46%), 2025E RMB 49.071 billion (+9.15%), 2026E RMB 51.580 billion (+5.11%) [5] - PE ratios: 2024E 14.81x, 2025E 13.38x, 2026E 12.28x [5] Market Data - Current share price: HKD 13.12 [3] - 52-week price range: HKD 11.80-22.10 [6] - Current market capitalization: HKD 73.131 billion [6]

股 票 研 究 [table_Authors] 钟浩(分析师) 沈唯(分析师) 021-38038445 0755-23976795 zhonghao027638@gtjas.com shenwei024936@gtjas.com [当前价格： Table_CurPrice] 40.18 登记编号S0880522120008 S0880523080006 公 司 更 新 报 告 52 周内股价区间（元） 36.83-61.50 总市值（百万元） 20,291 总股本/流通A股（百万股） 505/304 流通 B股/H 股（百万股） 0/0 [Table_Balance] 资产负债表摘要(LF) 股东权益（百万元） 3,554 每股净资产（元） 7.04 市净率（现价） 5.7 净负债率 -54.05% 证 券 研 究 报 告 [Table_Trend] 升幅(%) 1M 3M 12M 绝对升幅 9% -16% -32% 相对指数 11% -5% -12% 24 中报业绩符合预期，生科持续高增长 蓝晓科技(300487) 基础化工 [Table_Industry] /原材料 [Table_Invest] 评级： ...

Investment Rating - The report maintains a "Buy" rating for Shanghai Film (601595) with a target price of RMB 27.90, down from the previous target of RMB 35.28 [2] - The current stock price is RMB 18.17 [2] Core Views - The company's IP development business performed exceptionally well in H1 2024, with net profit exceeding the full-year 2023 results [3] - Major IP animation projects such as "Little Monster's Summer: Once Upon a Time in Langlang Mountain" and "Chinese Tales" Season 2 are expected to be released in 2025 [3] - The company's IP business is progressing faster than peers, with a projected 62.5% CAGR in net profit from 2024 to 2026 [9] Financial Performance - H1 2024 revenue reached RMB 380 million, up 2.4% YoY, with net profit attributable to shareholders of RMB 65.84 million, a 4.9% YoY increase [9] - Q2 2024 revenue declined 12.1% YoY to RMB 170 million, with net profit down 23.1% to RMB 22.97 million due to weak overall film market performance [9] - The company's subsidiary, Shangying Yuan, achieved RMB 64.05 million in revenue and RMB 21.16 million in net profit in H1 2024, representing 80.3% and 101% of 2023 full-year results respectively [9] Business Development - The company is actively transforming its cinema business by integrating "film + IP + space" resources to promote non-ticket innovative business growth [9] - Shanghai Film City SHO has hosted nearly 100 events, including film parties, premieres, and IP derivative activities [9] - The company is collaborating with Kaiying Network to launch an authorized game based on the "Black Cat Detective" IP, with other IP collaborations progressing steadily [9] Market Data - The stock's 52-week price range is RMB 16.43-34.43 [5] - Total market capitalization is RMB 8.144 billion [5] - The company has 448 million shares outstanding, all of which are A-shares [5] Financial Ratios - The current P/E ratio is 64.14x based on 2023 earnings, expected to decline to 29.17x by 2025 [10] - ROE is projected to increase from 7.7% in 2023 to 16.6% in 2026 [10] - Net profit margin is forecast to improve from 18.2% in 2023 to 32.4% in 2026 [11] Industry Comparison - The company's 2025E P/E ratio of 29.17x is higher than the peer average of 22.18x, reflecting its premium valuation due to faster IP business development [12] - Comparable companies include Hengdian Films (25.33x 2024E P/E), Enlight Media (21.58x), and Alpha Animation (41.86x) [12]

Investment Rating - Maintains an "Overweight" rating [2] - Target price adjusted to 15.24 yuan, down from the previous forecast of 26.10 yuan [2] - Current price stands at 12.14 yuan [2] Core Views - Retail revenue growth slowed, with gross margin declining due to proactive price adjustments [4] - Accelerated store openings impacted short-term profits, but future net profit margins are expected to improve as gross margins stabilize and new stores become profitable [4] - 2024H1 revenue reached 9.305 billion yuan (+7.26%), with net profit attributable to shareholders at 282 million yuan (-44.13%) [5] - Q2 2024 revenue was 4.206 billion yuan (-0.81%), with net profit attributable to shareholders at 52.05 million yuan (-80.29%) [5] - EPS forecasts for 2024-2026 revised to 1.28/1.57/1.86 yuan, down from previous estimates of 1.69/1.97/2.28 yuan [5] Business Performance - Retail and wholesale revenue growth in 2024H1 was +4.0% and +20.82%, respectively [5] - By product category, growth rates were +8.29% for Chinese and Western medicines, -13.41% for medical devices, and +34.42% for traditional Chinese medicines [5] - Diversified business, including personal care, cosmetics, food, and infant formula, generated 796 million yuan in revenue (+19.8%) [5] Gross Margin and Expenses - Gross margin in 2024H1 was 31.44%, down 2.12 percentage points, with retail and wholesale margins declining by 1.28 and 1.00 percentage points, respectively [5] - Q2 2024 saw a sequential improvement in gross margin by 2.38 percentage points [5] - Sales, management, and financial expense ratios increased by +0.50, -0.03, and +0.23 percentage points, respectively, due to higher wage costs [5] Regional Expansion - Total number of stores reached 11,291 by 2024H1, with 1,317 new stores opened in the first half, representing an 18% growth rate [5] - Stores outside the home province now account for 50.9% of the total, with key focus areas being Sichuan, Chongqing, Guangxi, Hainan, and Henan [5] - Revenue growth in the southwest region was 4.9%, while other regions grew by 18% [5] Financial Summary - 2024E revenue forecast at 19.005 billion yuan (+9.3%), with net profit attributable to shareholders at 760 million yuan (+38.3%) [6] - EPS for 2024E is projected at 1.28 yuan, with ROE at 9.3% [6] - P/E ratio for 2024E is 9.52, and P/B ratio is 0.88 [6] Valuation and Market Performance - 52-week stock price range: 11.40-26.22 yuan [6] - Total market capitalization: 7.236 billion yuan [6] - Stock price performance: -9% over 1 month, -42% over 3 months, and -46% over 12 months [9]

Investment Rating - Maintains an "Overweight" rating with a target price of 271.18 RMB [3][5] Core Views - The company's performance exceeded expectations, with significant growth in new products and a well-established national expansion strategy [3][12] - Revenue for H1 2024 reached 7.9 billion RMB, a 44% YoY increase, while net profit attributable to shareholders grew by 56% YoY to 1.7 billion RMB [3][12] - The company's "1+6" product diversification strategy is progressing steadily, with non-energy beverage revenue increasing by 6.94 percentage points to 12.81% of total revenue [3][12] - National market revenue outside Guangdong and Guangxi regions surged, contributing 65.95% of total revenue, up 9.43 percentage points YoY [3][12] - The number of terminal outlets exceeded 3.6 million, a 9.09% increase from the end of 2023 [3][12] Financial Performance - Gross margin for H1 2024 reached 44.6%, up 1.5 percentage points YoY, with Q2 gross margin at 46.05%, up 3.3 percentage points YoY [13] - Net profit margin for H1 2024 was 21.98%, up 1.69 percentage points YoY, with Q2 net profit margin at 24.29%, up 3.72 percentage points YoY [13] - Sales, management, R&D, and financial expense ratios decreased by 0.25, 0.55, 0.09, and 1.23 percentage points, respectively [13] Product and Channel Development - The energy drink category, led by Dongpeng Special Drink, grew by 33.5% YoY, driven by increased consumer demand for anti-fatigue products [12] - The new product "Hydration Drink" (补水啦) saw explosive growth, with revenue increasing by 281.1% YoY, becoming the company's second growth curve [12][13] - The company's channel strength continues to improve, with expanded terminal outlets and enhanced frozen product layouts during the summer peak season [13] Market and Valuation - The company's market capitalization stands at 91.178 billion RMB, with a total of 400 million shares outstanding [6] - The stock price range over the past 52 weeks was 162.67-239.88 RMB [6] - The company's P/E ratio for 2024E is 32.25, with an expected EPS of 7.07 RMB [4][5] Future Outlook - The company is expected to maintain strong growth, with projected revenue of 15.523 billion RMB in 2024, a 37.8% YoY increase [4] - Net profit attributable to shareholders is forecasted to reach 2.828 billion RMB in 2024, a 38.6% YoY increase [4] - The company's ROE is expected to rise to 36.0% in 2024, up from 32.3% in 2023 [4]